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1. Introduction 
Henoch-Schönlein purpura is one of the most common causes of systemic vasculitis. 
Henoch–Schönlein purpura typically affects children between the age of 3 and 10 years. The 
aetiology is unknown. Diagnosis includes palpable purpura (essential) in the presence of 
diffuse abdominal pain, acute arthritis/arthralgia, renal involvement characterized by 
haematuria and/or proteinuria (Ozen et al., 2006) and skin biopsy showing predominant 
IgA deposition in the walls of cutaneous vessels.  
In the majority of cases it is a self-limiting disease. Therefore, up to 40% of children with 
Henoch–Schönlein purpura require hospitalization for management of acute disease 
manifestations which may include nephritis, hypertension, severe pain, gastrointestinal 
bleeding or arthritis. Purpura occurs in all cases, joint pains and arthritis in 80% of cases, 
and abdominal pain in 62% of cases.  
The purpura typically appears on the legs and buttocks (Fig.1), but may also be seen on the 
arms, face and trunk. The abdominal pain is colicky, and may be accompanied by nausea, 
vomiting, constipation or diarrhea. There may be blood or mucus in the stools. Sometime 
finding includes a gastrointestinal haemorrhage, occurring in 33% of cases, due to 
intussusceptions (Saulsbury, 1999). The joints involved tend to be the ankles, knees, and 
elbows but arthritis in the hands and feet is possible; the arthritis is non-erosive and hence 
causes no permanent deformity. Problems in other organs, such as the central nervous 
system (brain and spinal cord) and lungs may occur, but much less commonly than the skin, 
bowel and kidneys (Saulsbury, 2001) 
 
 
Fig. 1. Henoch-Schönlein purpura in a 8 years old female child 
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Paediatric patients may develop glomerulonephritis within 4 to 6 weeks of the initial 
purpura presentation (Saulsbury, 2007). Renal involvement in Henoch-Schönlein purpura is 
transitory in most cases. Therefore, the long-term prognosis in Henoch-Schönlein purpura 
depends on the severity of renal involvement and can be poor when complicated by severe 
nephritis and chronic renal failure.   
2. Pathogenesis 
Henoch-Schönlein purpura nephritis is a systemic immune-complex mediated disease 
according to the clinical or histological pattern of recurrences of Henoch-Schönlein purpura 
nephritis in some patients after transplantation (Soler et al., 2005). The histological hallmark 
of Henoch-Schönlein purpura is severe inflammation of small vessels, particularly post-
capillary venules, with neutrophils, resulting in fibrinoid necrosis of vessel walls and 
extravasation of erythrocytes (Saulsbury, 1999). The clinical features are a consequence of 
general vasculitis due to IgA1 deposition in vessels and the renal measangium (Saulsbury, 
1999). Therefore, the pathogenetic mechanisms are still not fully understood.  
2.1 IgA immune complexes 
Similarly to IgA nephropathy, deposits of IgA-binding M proteins of group A streptococci 
were found on Henoch-Schönlein purpura kidneys. All Henoch-Schönlein purpura patients 
have IgA1-circulating immune complexes of small molecular mass. Therefore, only those 
with nephritis have large-molecular-mass IgA1-IgG-containing circulating immune 
complexes (Levinsky & Barratt, 1979). Large-molecular mass IgA-IgG complexes in the 
circulation are the major factor responsible for the formation of the nephritogenic immune 
complexes in patients with Henoch-Schönlein purpura nephritis. 
Some children with Henoch-Schönlein purpura nephritis subsequently have an episode or 
recurrent episodes of macroscopic hematuria, associated with upper respiratory tract 
infection without the other clinical features of Henoch-Schönlein purpura nephritis (Waldo, 
1988). Thus, these children’s clinical phenotype changes to that of IgA nephropathy. As the 
renal histologic and immunofluorescence microscopy findings in Henoch-Schönlein 
purpura nephritis are indistinguishable from those seen in patients with IgA nephropathy 
(Evans et al., 1973), it has long been ever speculated that Henoch-Schönlein purpura 
nephritis and IgA nephropathy have common pathogenetic mechanisms representing 
different ends of a continuous spectrum of disease (Waldo, 1988).  
Henoch-Schönlein purpura nephritis is similar to IgA nephropathy since IgA1, but not IgA2, 
is found in the circulating immune complexes and in mesangial immune deposits (Novak et 
al., 2007). IgA1-containing immune complexes are excreted in elevated amounts in the urine 
in patients with IgA nephropathy and Henoch-Schönlein purpura nephritis and may 
provide a specific marker for disease activity and/or severity in these patients (Suzuki et al., 
2008). IgA-binding M proteins may encounter circulatory IgA forming a complex with IgA-
Fc that could deposit in renal tissues (Schmitt et al., 2010).  
Reduced galactosylation of IgA1 O-glycans has been reported in patients with Henoch-
Schönlein purpura nephritis (Allen et al., 1998). Glycosylation defects are due to complex 
changes in expression of specific glycosyltransferases with reduced expression of ǃ1,3-
galactosyltransferase and elevated expression of GalNAc-specific ǂ2,6-sialyltransferase in 
patients with both IgA nephropathy and Henoch-Schönlein purpura nephritis, but not in 
patients with Henoch-Schönlein purpura without nephritis or healthy controls (Suzuki, 
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Moldoveanu et al., 2008). Due to their size, Galactose-deficient IgA1 containing immune 
complexes are less efficiently taken up by the asialoglycoprotein receptor in the liver and 
catabolised and their amounts increase in the circulation (Moura et al., 2004). Galactose-
deficient IgA1 leads to the formation of the circulating immune complexes.  These 
complexes may then deposit in the renal mesangium and incite, likely due to the binding to 
mesangial cells, to cellular activation (Lau et al., 2010). Consequently, mesangial cells start to 
proliferate and overproduce extracellular matrix components, cytokines and chemokines 
(Davin & Weening, 2003) leading to glomerular injury contributing to the pathogenesis of 
Henoch-Schönlein purpura nephritis.  
Glomerular depositions of other components, including kappa and lambda light chains, are 
also variably demonstrated in Henoch-Schönlein purpura nephritis. In patients with IgA 
nephropathy, lambda light chains were found predominantly over kappa light chains (Lai et 
al., 1996). 
2.2 Complement 
Complement activation appears to play an important role in the pathogenesis of IgA 
nephropathy and Henoch-Schönlein purpura nephritis, as glomerular complement 
activation may initiate the inflammatory cascade and enhance glomerular injury (Wyatt et 
al., 1987). Therefore, hypocomplementemia has been reported in some patients with 
Henoch-Schönlein purpura nephritis, and it is usually transient and not related to the 
severity of the diseases (Motoyama & Litaka, 2005). 
3. Incidence 
The estimated annual incidence of Henoch-Schönlein purpura in children is 10–20 per 
100,000 children (Rostoker, 2001). The annual incidence of Henoch-Schönlein purpura in 
Asian children [4.9 per 100,000] and African children [6.2 per 100,000] was significantly 
lower than Caucasian children [17.8 per 100,000].  
In childhood Henoch-Schönlein purpura, the male:female ratio ranges from 1.2−1.6 (Yang et 
al., 2005).  
Renal involvement occurs less frequently in children than adulthood (Yang et al.,  
2005; Pillebout et al., 2002). The incidence of nephritis in patients with Henoch-Schönlein 
purpura has been reported to be 15-62% with an estimated annual incidence of 20.4 per 
100,000 children (Gardner-Medwin et al., 2002; Shenoy, Bradbury, et al. 2007; Bogdanovic, 
2009).  
The overall incidence of Henoch-Schönlein purpura nephritis and the severity of Henoch-
Schönlein purpura nephritis in patients between 1987 and 1997 were similar to those in 
children between 1998 and 2008 and the number of patients with severe Henoch-Schönlein 
purpura nephritis has not decreased (Kawasaki et al., 2010). The overall incidence of 
Henoch-Schönlein purpura nephritis is rather stable over time.  
It could be estimated that 1–2% of all Henoch-Schönlein purpura nephritis patients will 
ultimately develop chronic kidney disease (Stewart et al., 1988; Narchi, 2005). A variable 
percentage of children (0−19%) with Henoch-Schönlein purpura nephritis may progress to 
renal failure or end stage renal disease (Ronkainen et al., 2002; Coppo et al., 1997; Goldstein 
et al., 1992; Kawasaki et al., 2003; Pillebout et al., 2002). In children with Henoch-Schönlein 
purpura nephritis followed up at tertiary centres the risk for progression to chronic kidney 
disease or end-stage renal disease is predicted to be 5–18% at 5 years, 10–20% at 10 years 
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and 20–32% at 20 years from the diagnosis (Goldstein et al., 1992; Coppo et al., 1997; Kaku et 
al., 1998; Bogdanovic, 2009).  
4. Clinical patterns 
The average duration of Henoch-Schönlein purpura symptoms is 4 weeks. The majority of 
patients experience resolution of symptoms within 2 to 3 months. Approximately 30% of 
patients have one or more recurrences after the resolution of initial symptoms (Saulsbury, 
1999; Trapani et al., 2005). Therefore, purpura lasting longer than 1 month or relapsing 
disease are associated with the development of nephritis(Rigante et al., 2005; Shin, Park, et 
al., 2006). Patients showing abdominal pain as the initial symptom had a higher probability 
of developing nephrotic syndrome. Persistent rash was a poor prognostic factor for Henoch-
Schönlein purpura nephritis (Hung et al., 2009).  
Renal signs are manifested in the majority of Henoch-Schönlein purpura patients from 3 
days to 17 months after onset of the disease (Kaku et al., 1998), occurring more frequently 
within the first 3 months (Sano et al., 2002). In few cases the renal disease may develop even 
years after the initial presentation (Mollica et al., 1992). While abnormalities on urinalysis 
may continue for a long time, only 1% of all Henoch-Schönlein purpura patients develop 
chronic kidney disease (Saulsbury, 2001).  
Nephritis is the one feature of Henoch-Schönlein purpura that may have chronic 
consequences. The long-term prognosis is largely dependent on the severity of nephritis 
(Narchi, 2005; Mir et al., 2007). Renal manifestations of the disease ranged from mild, benign 
involvement, intermittent haematuria and proteinuria, to rapidly progressive or crescentic 
nephritis. Of the 40% of patients who develop kidney involvement, almost all have evidence 
(visible or on urinalysis) of blood in the urine. More than half also have proteinuria, which 
in one eighth is severe enough to cause nephrotic syndrome (Saulsbury, 2001). From a 
retrospective study, nephritis occurred in 46% of the Henoch-Schönlein purpura patients, 
consisting of isolated haematuria in 14%, isolated proteinuria in 9%, both haematuria and 
proteinuria in 56%, nephrotic-range proteinuria in 20% and nephrotic-nephritic syndrome in 
1% (Jauhola et al., 2010).  
Renal involvement is in most cases mild and self-limited in children. Henoch-Schönlein 
purpura nephritis in children had a lower risk of progression to renal insufficiency than 
adults. Gross hematuria and lower extremity edema were less frequent in the children than 
adults (Hung et al., 2009).  Morbidity is low in patients with Henoch-Schönlein purpura 
who have hematuria and mild proteinuria at onset, while it is higher among those with 
more severe renal disease, as in a nephritic, nephrotic or a nephritic/nephrotic signs (Coppo 
et al., 2006; Ronkainen et al., 2002; Narchi, 2005; Goldstein et al., 1992). The main clinical 
signs of rapidly progressive Henoch-Schönlein purpura nephritis at presentation were 
edema, hypertension, gross hematuria, and oliguria (Oner, 1995). End-stage renal disease 
was associated with nephritic and/or nephrotic syndrome at presentation in nearly all 
children with Henoch-Schönlein purpura nephritis (Soylemezoglu et al., 2009). The highly 
variable clinical course of Henoch-Schönlein purpura nephritis has been related to the 
marked variability in histopathologic presentation at renal biopsy, with glomeruli ranging 
from histologically normal to diffuse proliferative and crescentic lesions (Assadi, 2009). 
4.1 Classification 
Five categories of Henoch-Schönlein purpura nephritis were identified according to renal 
manifestations at disease onset (Falkner et al., 2004): (A) micro/macroscopic hematuria or 
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persistent mild proteinuria (< 1 g/L or urine albumin/creatinine ratio < 200 mg/mmol);  
(B) persistent mild proteinuria (< 1 g/L or urine albumin/creatinine ratio < 200 mg/mmol) 
and micro- or macroscopic hematuria; (C) nephritic syndrome (moderate proteinuria and 
urine albumin/creatinine ratio ≥ 200–400 mg/mmol), decreased glomerular filtration rate, 
hematuria and/or hypertension, or nephrotic syndrome (urinary albumin excretion  
> 40 mg/hour/m2 body surface area or urine albumin/creatinine ratio ≥ 400 mg/mmol, 
serum albumin < 25 g/L; (D) acute progressive glomerular nephritis; (E) chronic glomerular 
nephritis. Classes A and B were considered as mild renal disease, and classes C to E as 
severe disease (Meadow et al., 1972).  
Another clinical evaluation categorized the patients according to four stages. Stage (A) is 
considered normal: the patient was normal on physical examination, with normal urine and 
renal function; stage (B) had minor urinary abnormalities: the patient was normal on 
physical examination, with microscopic hematuria or proteinuria of less than 20 mg/m2/h; 
stage (C) had persistent nephropathy: the patient had proteinuria of 20 mg/m2/h or greater 
or hypertension and a 24-h creatinine clearance of 60 ml/ min/1.73 m2 or greater; stage (D) 
had renal insufficiency: the patient had a 24-h creatinine clearance of less than 60 
ml/min/1.73 m2, including dialysis/transplant or death (Kawasaki et al., 2010).  
4.2 Serum IgA  
Although serum IgA levels are higher in children with Henoch-Schönlein purpura / 
Henoch-Schönlein purpura nephritis than in controls, this serum abnormality does not 
constitute a sensitive diagnostic marker of Henoch-Schönlein purpura with or without 
nephritis. In particular, over 40% children with Henoch-Schönlein purpura had elevated 
serum IgA levels at presentation. Therefore, the difference in serum IgA levels between 
patients with and without nephritis was not statistically significant. 
4.3 Renal biopsy  
Renal involvement can be severe but may resolve completely. Therefore, some children will 
develop long-term sequelae. The renal biopsy is helpful in determining the need for 
treatment with immunosuppression in the acute phase (McCarthy & Tizard, 2010).  
The criteria for renal biopsy were defined as follows: (1) the patients had proteinuria of 20 
mg/m2/hour or greater and haematuria or (2) the patients had proteinuria of less than 20 
mg/m2/hour and recurrent macrohematuria (Kawasaki et al., 2010). According to another 
recent review a renal biopsy has been recommended in the following situations: (1) acute renal 
impairment/nephritic syndrome at presentation; (2) nephrotic syndrome with normal renal 
function persisting at 4 weeks; (3) nephrotic range proteinuria (urine protein/creatinine ratio, 
>250 mg/mmol) at 4–6 weeks (if not improving spontaneously); (4) persistent proteinuria-
urine protein/creatinine ratio >100 mg/mmol for more than 3 months. Consider biopsy 
particularly if the diagnosis is not clear (McCarthy & Tizard, 2010). 
Renal involvement in Henoch-Schönlein purpura is quantified by means of a kidney biopsy 
(Fig. 2), which may demonstrate positive mesangial staining and positive anti-IgA antisera on 
immunofluorescence, with glomerular changes graded chiefly according to the Henoch-
Schönlein purpura nephritis classification described in the International Study of Kidney 
Disease in Children (Rai et al., 1999; Sheno, Bradbury, et al. 2007; Ronkainen et al., 2006). The 
grading of renal histology has been considered as an important marker of outcome (Farine et 
al., 1986). The classification provided by the Study of Kidney Disease in Children included 
grade I: minimal alterations; grade II: mesangial proliferation; grade III: focal or diffuse 
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proliferation or sclerosis with <50% crescents; grade IV: focal or diffuse mesangial proliferation 
or sclerosis with 50–75% crescents; grade V: focal or diffuse mesangial proliferation or sclerosis 
with >75% crescents; grade VI: membranoproliferative-like lesions (Counahan et al., 1977).  
 
A
B
 
Fig. 2. Methenamine-silver stain of a glomerular of a patient with Henoch-Schönlein 
purpura nephritis showing diffuse mesangial and focal endocapillary proliferation (panel 
A). The immunofluorescence studies showed intense IgA positivity (3+) (panel B); 
complement C3 staining was also mildly positive (1+).  
5. Risk factors 
5.1 Renal involvement in Henoch-Schönlein purpura 
Some authors attempted to identify prognostic factors for a child with Henoch-Schönlein 
purpura to develop nephritis by using univariate and multivariate analysis models. The 
independent risk factors for Henoch-Schönlein purpura nephritis were persistent purpura, 
severe abdominal symptoms and age above 4 or 7 or 10 years. Other independent risk 
factors were relapse or decreased serum factor XIII activity (Kaku et al., 1998; Sano et al., 
2002; Rigante et al., 2005; Shin, Park, et al., 2006; Ronkainen et al., 2006). Persistent purpura, 
severe abdominal symptoms and an older age were confirmed as the most significant risk 
factors for later nephropathy (Bogdanovic, 2009). A prospective study showed that age over 
8 years at onset (OR 2.7), abdominal pain (OR 2.1) and a recurrence of Henoch-Schönlein 
purpura disease (OR 3.1) were independent risk factors for developing nephritis(Jauhola et 
al., 2010). 
5.2 Long-term renal impairment 
Severe renal involvement at onset of Henoch-Schönlein purpura is in general predictive of a 
poor renal outcome. The independent predictors of a poor renal outcome were severe initial 
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presentations with renal failure, nephritic, nephrotic syndrome or mixed syndrome and the 
percentage of glomeruli with crescents (Mir et al., 2007). Some few children with mild renal 
symptoms at onset have a poor long-term outcome. Thus, long-term follow-up is mandatory 
also for these patients (Algoet & Proesmans, 2003; Goldstein et al., 1992). 
6. Follow-up 
A clinical pathway was recommended if there is evidence of haematuria, proteinuria, renal 
impairment or hypertension in patients with Henoch-Schönlein purpura (Tizard & Hamilton-
Ayres, 2008). Prospectively and systematically collected data suggested that weekly urine 
dipstick tests should be continued for 2 months from the onset of Henoch-Schönlein purpura. 
Beyond that point frequent routine follow-up is neither cost-effective nor necessary in patients 
with no urine abnormalities during follow-up. However, the length of follow-up time should 
be increased at least up to 6 months individually in the case of Henoch-Schönlein purpura 
recurrence and in those developing nephritis (Jauhola et al., 2010). 
7. Prevention of Henoch-Schönlein purpura nephritis 
Intervention to shorten the duration of Henoch-Schönlein purpura and prevent relapses 
may be helpful in preventing the development of nephritis. However, no therapy has yet 
been shown to decrease the duration of Henoch-Schönlein purpura, prevent recurrences, or 
prevent the development of nephritis (Saulsbury, 2009). 
Studies reported on patients with Henoch-Schönlein purpura lacking clinical signs of 
nephropathy at admission were treated with prednisone at doses ranging from 1.0 to  
2.5 mg/kg/day over a period of 7–21 days. Early prednisone treatment did not succeed in 
reducing the risk of further renal complication from Henoch-Schönlein purpura. Although 
prednisone is effective in alleviating the abdominal pain and joint pain associated with 
Henoch-Schönlein purpura, it did not short the duration of the disease, prevented the 
recurrences, or prevented the development of nephritis (Ronkainen et al., 2006). The 
relatively small subgroup of Henoch-Schönlein purpura patients who may benefit from 
corticosteroids included those who present with renal involvement and probably those with 
severe abdominal symptoms requiring medical attention (Mollica et al., 1992; Saulsbury, 
1999; Narchi, 2005).  
In general, the prophylactic treatment with prednisone at 2 mg/kg/day in Henoch-
Schönlein purpura must be considered of value if (1) there is a quicker resolution of 
abdominal pain, considering the cost and potential damage from prolonged treatment; (2) 
the treatment performed during the acute phase reduce the rates of abdominal surgery for 
exploration or actual intestinal injury; (3) the avoidance of several late-onset medical 
conditions, including hypertension, preeclampsia, and persistent nail-fold capillary changes, 
suggesting a chronic vasculitis (Gibson et al., 2008). Such measure at this time has not been 
demonstrated. However, 2– 4 weeks of prednisone administration at doses ranging from 1.0 
to 2.5 mg/kg per day over a period of 7–21 days or intravenous methylprednisolone 
prophylaxis (5 mg/kg four to six times per day for 3–5 days) failed to prevent renal 
involvement in Henoch-Schönlein purpura after 0.5–1 years (Zaffanello et al., 2009).  
Dapsone, an antileprotic drug, has been used at 1–2 mg/kg/day daily in a few patients with 
prolonged in Henoch-Schönlein purpura, improving the time of purpuric rush, but it has 
not been studied in a rigorous fashion in children with nephritis (Iqbal & Evans, 2005).  
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The clinical course of patients in a report suggested that colchicines, an ancient anti-
inflammatory drug, may be effective treatment at dosages of 1.2 mg/day in children with 
prolonged Henoch-Schönlein purpura possibly preventing the development of nephritis 
(Saulsbury, 2009). Therefore, at the current time insufficient data are available to support a 
recommendation for prophylaxis. 
8. Conventional treatment 
Conventional therapies were defined as drugs or procedures that act as immune 
modulators. 
8.1 Treatment of mild form of Henoch-Schönlein purpura nephritis 
Patients with mild renal symptoms have showed lower proportion of poor outcome than 
those with severe renal symptoms. In particular, patients with isolated hematuria showed a 
good prognosis, but 18% of patients with mild proteinuria at onset showed a poor outcome 
(Edström Halling et al., 2010). For this reason patients would be followed until full clinical 
resolution of renal symptoms. Since the level of proteinuria at onset does not seem to be a 
reliable predictor of outcome, the persistence of mild proteinuria in the long-term follow-up 
(one year) may require renal biopsy. Finally, the treatment of mild clinical form must be 
weighed according to International Study of Kidney Disease in Children grading score  
(see 8.2. and 8.3. sections).  
8.2 Treatment of moderately severe Henoch-Schönlein purpura nephritis 
Patients affected by moderately-severe proteinurias were treated with prednisone, 
intravenous gamma globulins and tonsillectomy, while pulse methylprednisolon and 
cyclophosphamide were introduced according to the degree of severity of renal histology.  
Three Henoch-Schönlein purpura nephritis patients treated by means of intravenous  
(2 g/kg/month) and intramuscular gamma globulins (0.35 ml/kg every 15 days) showed 
improved degrees of proteinuria and acuity index at renal biopsy (Rostoker et al., 1994; 
Rostoker et al., 1995). The administration of the angiotensin converting enzyme inhibitor 
(enalapril 10 mg/day) combined with fish oil led to a significant reduction in protein 
excretion rate after a few weeks of treatment in case series (Dixit et al., 2004). Additionally, 
tonsillectomy proved to be effective in five patients affected by Henoch-Schönlein purpura 
nephritis (Sanai &  Kudoh, 1996) as well as in 16 children with Henoch-Schönlein purpura 
nephritis in combination with intravenous pulse methylprednisolon at a dose of  
1 gram/1.73 m2 of body surface area (three to four cycles), prednisone (2 mg/kg/day) and 
cyclophosphamide (2 mg/kg/day) (Inoue et al., 2007).  
Data obtained from the literature are insufficient to support the use of specific treatments, such 
as intravenous gamma globulins and angiotensin converting enzyme inhibitors, in moderate-
severe Henoch-Schönlein purpura nephritis, based on case series (Zaffanello et al., 2009).  
8.3 Treatment of rapidly progressive or crescentic Henoch-Schönlein purpura 
nephritis 
Predictors of treatment with immunosuppression drugs were higher albuminurias and 
urine immunoglobulin G, and lower glomerular filtration rate at onset and a higher 
International Study of Kidney Disease in Children grading score in the biopsy. 
Unfortunately, no significant difference in outcome was found between the treated and 
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untreated patients with crescents. Neither was there any significant difference in glomerular 
filtration rate between treated and untreated patients (Edström Halling et al., 2010). 
Several studies have reported that patients with severe Henoch-Schönlein purpura nephritis 
may benefit from an intravenous pulse of methylprednisolone (Kawasaki et al., 2003; 
Niaudet & Habib, 1998; Edström Halling et al., 2010), cyclosporine A (Ronkainen et al., 
2003), cyclophosphamide (Kawasaki et al., 2004; Tarshish et al., 2004; Shenoy et al., 2007; 
Kawasaki et al., 2004; Edström Halling et al., 2010), urokinase pulse therapy (Kawasaki et 
al., 2003; Zaffanello et al., 2007), azathioprine (Zaffanello et al., 2007; Foster et al., 2000), and 
plasma exchange therapy (Scharer et al., 1999). All severe cases almost received angiotensin 
converting enzyme inhibitors and/or angiotensin II receptor blockers combined with 
immunosuppressant drugs (Edström Halling et al., 2010).  
Some protocols of treatment for Henoch-Schönlein purpura nephritis included the 
prescription of a single specific immunosuppressive treatment; other included two or 
multiple immunosuppressive drugs.  
8.3.1 Steroids 
Steroids included prednisolone or methylprednisolone at 30 mg/kg/day for 3 consecutive 
days or dexamethasone at 5 mg/kg/day (Kawasaki et al., 2003; Niaudet &  Habib, 1998). 
Fifty-six patients with renal lesions graded as IIIb or higher were treated with 
intravenous/oral steroids, along with dipyridamole and anticoagulant warfarin. The acuity 
index decreased at second biopsy, whereas the chronicity index did not differ significantly 
(Kawasaki et al., 2003).  
8.3.2 Cyclosporine A 
Single treatment included cyclosporine A performed for 6 months - 2 years (Ronkainen et 
al., 2003).  
Cyclosporine A, at the initial dose of 4–8 mg/kg/day, with blood level kept at 150–200 μg/L, 
and at the maintenance dose of 1–5 mg/kg/day, with blood level kept at 80–100 μg/L, proved 
to be effective in some case series with biopsy-proven steroid-resistant Henoch-Schönlein 
purpura nephritis. In particular, the treatment was effective in reducing the nephrotic 
proteinuria range after an average of 2 months in seven patients. Stable remission after a mean 
follow-up of 6 years was achieved in four subjects (Ronkainen et al., 2003). Treatment with 
cyclosporine A was effective in one patient with renal crescents following the failure of pulse 
steroid, oral prednisone and an 8 months course of azathioprine at 2 mg/kg/day (Shin et al., 
2006). In seven patients, treatment with pulse or oral prednisone and cyclosporine A with or 
without angiotensin converting enzyme inhibitor cilazapril displayed a marked efficacy in 
reversing nephrotic-range proteinuria and reducing histological grading post-treatment (Shin 
et al., 2005). In another study involving a group of 82 children with varying degrees of renal 
manifestation and histology (Mir et al., 2007), the majority received steroid treatment while 
only a few were treated with angiotensin converting enzyme inhibitor or cyclophosphamide in 
combination with steroids. Despite treatment, the long-term prognosis worsened markedly in 
those children manifesting severe clinical presentation. 
8.3.3 Cyclophosphamide 
Single treatments included cyclophosphamide performed for 8-12 weeks (Tarshish et al., 
2004; Zaffanello et al., 2007).  
A case series of patients with biopsy-proven Henoch-Schönlein purpura nephritis displayed 
varying degrees of response to cyclophosphamide at 2-2.5 mg/kg/day. Several patients in 
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whom the initial renal biopsy had revealed ≥80% crescentic glomeruli received 
cyclophosphamide in combination with pulse of methylprednisolone and/or long-term oral 
prednisone. The combined treatment was effective in aiding clinical recovery, maintaining 
normal renal function and reducing grade histology. Unfortunately, the lack of control 
patients and the small number of patients treated or short follow-up period hamper the 
drawing of firm conclusions (Zaffanello et al., 2007; Zaffanello et al., 2009).  
Long-term outcome of patients treated with daily cyclophosphamide expressed as end-stage 
renal disease did not differ with controls (Tarshish et al., 2004), indicating failure at level II 
of evidence. In a retrospective investigation, 21 children with crescents in 40% of glomeruli 
who were treated with an association of azathioprine at 1-2 mg/kg/day and steroids 
displayed an effective clinical outcome. Unfortunately, the considerable variability of the 
histological patterns complicated any interpretation of the results obtained (Bergstein et al., 
1998; Foster et al., 2000). Moreover, nine patients with severe histologically graded lesions 
were prescribed aggressive therapy with azathioprine and steroids, leading to marked 
clinical improvement. Regrettably, histological outcome was not reported, thus hindering 
the drawing of sustainable conclusions (Singh et al., 2002). Lastly, ten children treated with 
steroids and azathioprine were compared to ten patients receiving steroids alone. The initial 
biopsy revealed histological lesions comparable to those observed at follow-up, although 
mesangial IgA depositions were reduced in the majority of patients (Shin et al., 2005). 
However, the small number of patients studied led to difficulties in interpreting results. 
8.3.4 Mycophenolate mofetil 
Mycophenolate mofetil at 900-1,200 mg/m2/day was tested in patients with vasculitis and 
connective tissue disease involving the kidney, one of whom was affected by Henoch-
Schönlein purpura nephritis. This drug was administered subsequent to the failure of 
treatment with steroids and azathioprine (Filler et al., 2003). However, two patients featuring a 
prolonged course of nephritis were first prescribed steroids and azathioprine with the 
subsequent addition of mycophenolate mofetil (Algoet & Proesmans, 2003). Once again, due to 
the exceedingly low number of patients treated, no firm conclusions could be drawn.  
8.3.5 Single or combined treatment 
Other protocols were performed with double immunosuppressant therapy, including steroid–
cyclophosphamide (Oner et al., 1995; Iijima et al., 1998; Flynn et al., 2001; Tanaka et al., 2003; 
Kawasaki et al., 2004; Mir et al., 2007), steroid combined with azathioprine for 8-15 months 
(Bergstein et al., 1998; Foster et al., 2000; Singh et al., 2002; Shin et al., 2005; Zaffanello et al., 
2007), and steroid– cyclosporine A or steroid – (angiotensin converting enzyme inhibitors) – 
cyclosporine A (Shin et al., 2005; Shin et al., 2006; Shin et al., 2007).  
Triple immunosuppressant therapy was carried out using steroid– cyclophosphamide – 
azathioprine (Shenoy et al., 2007) and steroid– azathioprine –mycophenolate mofetil (Algoet 
et al., 2003; Zaffanello et al, 2007).  
8.3.6 Evidence based treatment 
The majority of reports provide scarce support to the various treatment options identified in 
cases of severe childhood Henoch-Schönlein purpura nephritis (Zaffanello et al., 2009). As 
the Henoch-Schönlein purpura nephritis and IgA nephropathy have identical pathogenesis 
and renal lesions, for which current evidence supports the use of immunosuppressive drugs 
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in patients with severe disease (Samuels et al., 2003; Cheng et al., 2009), the treatment 
protocols with proven significant benefit in IgA nephropathy should be used in children 
having Henoch-Schönlein purpura nephritis of comparable severity (Bogdanovic, 2009). A 
recent, single-centre, retrospective review looking at treatment of severe Henoch-Schönlein 
purpura nephropathy and IgA nephropathy demonstrated that therapy with differing 
combinations of steroids, cyclophosphamide, angiotensin converting enzyme inhibitors and 
angiotensin receptor blockers produced a good outcome in 54% of children with severe 
(>stage III) histological changes on initial renal biopsy (Edström Halling et al., 2009). For this 
reason, many physicians prescribe similar treatments in Henoch-Schönlein purpura patients 
with nephritis, despite the lack of disease-specific data, although IgA nephritis lesions 
however, tend to have a less severe inflammatory component and clinical trials on IgA 
nephropathy often include adult patients, while Henoch-Schönlein purpura nephropathy is 
primarily a disease that develops in children (Zaffanello et al., 2010).  
Moreover, several patients with moderately severe Henoch-Schönlein purpura nephritis 
(histological grade I–III and serum albumin >2.5 g/dl) were treated with angiotensin-
converting enzyme inhibitors and/or angiotensin receptor blockers. Patients with Henoch-
Schönlein purpura nephritis exceeding grade III or serum albumin ≤ 2.5 g/dl received 
combination therapy comprising prednisolone at 2 mg/kg/day, given in three divided 
doses (maximum dose, 80 mg/day) for the first 4 weeks, followed by prednisolone at  
2 mg/kg given as a single dose every other morning for 8 weeks, immunosuppressant 
azathioprine at 2 mg/kg/day as a single dose (maximum dose 100 mg) or mizoribine at  
5 mg/kg/day as a single dose (maximum dose 300 mg) maintained for 6 months, and 
warfarin at 1 mg/day given as a single dose each morning. The warfarin dose was then 
adjusted to give a thrombo-test result of 20–50%, and dipyridamole started at 3 mg/kg/day 
given in three divided doses, increased to 6 mg/kg/day (maximum dose, 300 mg/day) 
maintained for 8 weeks if the patient experienced no adverse effects, such as headache. The 
resolution of proteinuria, without renal dysfunction, was 50% at 5.2 months, 80% at  
8.5 months, and 90% at 11.1 months (Ninchoji et al., 2011). 
8.4 Plasma exchange 
Patients featuring rapid progression of Henoch-Schönlein purpura nephritis, despite the 
treatment with immunosuppressive medications (steroids, azatioprine and 
cyclophosphamide), were treated with plasma exchange. Among these children, 36% 
developed end-stage renal disease between 1 and 7 years after the initiation of treatment 
(Gianviti et al., 1996). The other children showed a reduction of glomerular filtration rate and 
crescents > 50% of glomeruli and continued plasma exchange treatment (Hattori et al., 1999).  
A case series of eight children with a rapidly progressive course of disease treated with plasma 
exchange, the beneficial effects produced were only transient, and, despite repeated plasma 
exchange, the subjects progressed to end-stage renal disease after 1–4 years (Scharer et al., 
1999). In case series study, children with extensive crescent formation underwent plasma 
exchange followed by multiple drug therapy, including steroids, pulse urokinase and 
cyclophosphamide. The patients manifested a decrease in acuity index and percentage of 
glomeruli with crescents, whereas the chronicity index remained unchanged (Kawasaki et al., 
2004). Plasma exchange was recently performed in patients with a histology grading of at least 
III at renal biopsy. At follow-up, only one child treated later in the course of the disease 
underwent a kidney transplant. At the end of the study, the investigators reported that the 
early performing of plasma exchange may delay the rate of progression of cellular crescents to 
the fibrotic stage and end-stage renal disease (Shenoy et al., 2007).  
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Plasma exchange in patients with Henoch-Schönlein purpura nephritis, either alone or in 
combination with immunosuppressant, cannot currently be recommended due to the 
paucity of data available (Zaffanello & Fanos, 2009). 
8.5 Adjuvant treatment 
Adjuvant therapies were defined as any secondary treatment used in addition to the 
primary or conventional treatments that increased the likelihood of cure (eg, intravenous 
immunoglobulins, anticoagulants, enzymes and vitamins). Results on moderate urinary 
abnormalities and severe Henoch-Schönlein purpura nephritis are reported separately 
because the renal implications, clinical monitoring, and conventional treatment modalities 
differ in terms of outcome measures (Zaffanello et al., 2009). 
8.5.1 Moderate urinary abnormalities 
Adjuvant treatment in children with isolated proteinuria with or without nephrotic 
syndrome has been reviewed (Zaffanello et al., 2009). 
Two studies (Rostoker et al., 1995; de Almeida et al., 2007) reported the usefulness of  
3 months treatment with intravenous immunoglobulins (2 g/kg/month) followed by 
intramuscular immunoglobulins (0.35 mL/kg) twice a month for 8 months in treating 
nephritis with significant proteinuria. Both the severity of proteinuria and the acuity index 
significantly improved in the majority of these patients with renal histology of stage III and 
normal renal function. In patients with severe gastrointestinal involvement who did not 
respond to methylprednisolone, were administered intravenous immunoglobulins at 2 g/kg 
in a single dose (Rostoker et al., 1998; Aries et al., 2005). Finally, the efficacy of intravenous 
immunoglobulins (2 g/kg, infused over 10–12 hours) in inhibiting the progression of the 
disease has been tested although only in unstructured case series.  
Intravenous administration of Factor XIII concentrate from 30 to 50 U/kg for 3 days was 
associated with significant improvements in the severity of proteinuria and hematuria 
compared with non-treated group (Erdoğan et al., 2003).   
In children aged 3 to 15 years with Henoch-Schönlein purpura nephritis, tocopherol  
300 mg/day was to be administered for 6-17 weeks (Kaku et al., 1998). Oxidative damage 
and worsening of the clinical course were observed despite significant increases in mean 
plasma vitamin E concentration. In 5 children with biopsy-proven Henoch-Schönlein 
purpura nephritis, treatment with an angiotensin-converting enzyme inhibitor (enalapril) 
for hypertension and adjuvant treatment with fish oil 1 g twice a day as an antioxidant was 
associated with significantly decreased severity of proteinuria, decreased blood pressure, 
and stable serum creatinine concentration and glomerular filtration rate. The limitation of 
this study was the small sample size and the confounding antiproteinuric effect of the 
angiotensin-converting enzyme inhibitor (Dixit et al., 2004; Chiurchiu et al., 2005).  
A systematic review reported no clear benefit of the use of dipyridamole (3-6 mg/kg/day 
for 8 weeks) and heparin (adjusted to maintain activated partial thromboplastin time 
between 60 and 80 seconds for 4 weeks) in treating Henoch-Schönlein purpura nephritis, 
with limitations being the small number of studies, small sample size, and poor 
methodology of the studies (Chartapisak et al., 2009).   
8.5.2 Severe Henoch-Schönlein purpura nephritis   
Adjuvant treatments of severe Henoch-Schönlein purpura nephritis with crescent 
formations in children have been studies from a systematic review (Zaffanello et al., 2009).  
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The patients with severe Henoch-Schönlein purpura described in these articles had 
nephrotic syndrome, Henoch-Schönlein purpura nephritis, rapidly progressive 
glomerulonephritis, and/or kidney failure. Histology of kidney biopsies found a significant 
proportion with crescent formations (International Study of Kidney Disease in Children 
grade IV–V). These patients were at high risk for kidney failure despite aggressive treatment 
with cocktails that included adjuvant anticoagulants or antiplatelet agents such as heparin 
(Iijima et al., 1998), warfarin (Kaku et al., 1998; Iijima et al., 1998; Kawasaki et al., 2004) 
dipyridamole (Oner et al., 1995; Kaku et al., 1998; Iijima et al., 1998; Mir et al., 2007) and 
acetylsalicylic acid (Mir et al., 2007). Treatments associated conventional with adjuvant 
therapy including three days intravenous pulse of methylprednisolone and/or long-term 
oral prednisolone administration for 6 months (Oner et al., 1995; Kawasaki et al, 2003; 
Kawasaki et al., 2004; Mir et al., 2007). Intravenous steroids were used alone (Kawasaki et 
al., 2003) or in combination with (or to replace) cyclophosphamide(Oner et al., 1995), or 
comparable steroid pulse therapy was used with cyclophosphamide (Kawasaki et al., 2004; 
Mir et al., 2007) and Cyclosporine A (Mir et al., 2007). Oral steroid therapy was used alone 
or in combination with cyclophosphamide (Iijima et al., 1998; Tanaka et al., 2003; Shekelle et 
al., 1999). 
In  a case series of 12 children aged 6 to 14 years with Henoch-Schönlein purpura, quadruple 
therapy with cyclophosphamide for 2 months, intravenous pulse methylprednisolone for 3 
days, oral prednisone for 3 months, and adjuvant oral dipyridamole for 6 months, 
glomerular filtration rate normalized in 11 patients and 7 patients had complete remission 
(Oner et al., 1995). In a case series of 14 children followed up for a mean (standard 
deviation) of 7.5 (0.9) years, combination treatment consisted of prednisone for 12 weeks, 
cyclophosphamide for 8 weeks, and adjuvant intravenous heparin  for 4 weeks followed by 
warfarin 1 mg/day for 4 weeks, and dipyridamole for 8 weeks . The histologic abnormalities 
of the kidney significantly improved in the meantime (Iijima et al., 1998).  
In 2 clinical trials, cyclosporine A was used for the treatment of severe Henoch-Schönlein 
purpura nephritis in children, either alone (Ronkainen J, 2003) or in combination with steroids 
and adjuvant dipyridamole (Mir et al., 2007). In particular, a retrospective, nonrandomized 
study in 82 children, prednisone or pulse methylprednisolone and cyclophosphamide and 
cyclosporine were given; asetil salicylic acid or dipyridamole were given as adjuvant therapy, 
although their dosing were not reported as well. In 35% of nephrotic patients and 62% of 
nephritic patients showed complete remission after 6 months and long-term course (Mir et al., 
2007). In a case series of 13 patients with renal histology grade IIIb or IVb, prednisone was 
administered for 26 weeks and cyclophosphamide was administered for 8 weeks (Tanaka et 
al., 2003). Adjuvant therapy was dipyridamole 5 mg/kg/day (maximum, 300 mg/day).  
At study end, acuity index was significantly decreased, chronologic index was unchanged, 
and renal histology grade was improved significantly (Tanaka et al., 2003).  
In a controlled study, 26 in 37 children with severe Henoch-Schönlein purpura nephritis, 
triple therapy with oral cyclophosphamide for 12 weeks, pulse methylprednisolone for 3 
days, and intravenous pulse urokinase at 5000 U/kg/day (maximum, 180,000 U) for 7 
consecutive days was effective. Thus, after 6 months, severity of proteinuria and mesangial 
IgA deposition were significantly reduced (Kawasaki et al., 2003; Kawasaki et al., 2004). 
Observations were reported in retrospective case series, and the literature lacks reports of 
substantial clinical trials. Because the literature search did not find any well-structured 
studies reporting benefits of the use of antiplatelet agents or heparin in children with 
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Henoch-Schönlein purpura nephritis, the use of such therapy is not recommended at this 
time since lack of evidence from well structured clinical trials (Zaffanello et al., 2009). 
9. Prognosis 
9.1 Prognostic factors and clinical findings 
Age at onset has not been shown to be a predictor of poor outcome (Ronkainen et al., 2002; 
Coppo et al., 1997; Counahan et al., 1977; Edström Halling et al., 2010). In the long-term, the 
morbidities of Henoch-Schönlein purpura are predominantly attributed to the intensity of 
renal involvement at presentation. Anymore, the majority of patients that first manifest 
nephropathy during childhood will not reach end stage renal disease before adulthood 
(Wyatt & Hogg, 2001). 
Female had a markedly greater risk of a poor long-term outcome (Edström Halling et al., 
2010).  
Patients with isolated hematuria showed a good prognosis (Narchi, 2005), with some 
exceptions (Goldstein et al, 1992). Most children with Henoch-Schönlein purpura nephritis 
who present only with hematuria and/or low-grade proteinuria at onset have good 
probabilities of recovery (Mir et al., 2007). Only patients showing normal urinalysis for 6 
months may be discharged from follow-up. In view of the possibility of late deterioration in 
those with mild renal involvement, long-term albeit annual follow-up was recommended 
(Narchi, 2005). It has been calculated that 18% of patients with mild proteinuria at onset 
progress towards poor outcome (Ronkainen et al., 2002; Butani & Morgenstern, 2007; 
Edström Halling et al., 2010).  
Of children who at onset displayed mild symptoms, 72% achieved a complete recovery, 
compared to 47% of those with severe symptoms. Of children who had mild symptoms at 
onset, 15% had a poor outcome compared to 41% of those with severe symptoms (Edström 
Halling et al., 2010). 
Henoch-Schönlein purpura nephritis patients with nephritic/nephritic syndrome and 
massive proteinuria (Niaudet & Habib, 1998) are considered to have severe disease 
(Kawasaki et al., 2003; Niaudet & Habib, 1998). Therefore, no significant difference in 
outcome was found between patients with nephrotic versus non-nephrotic proteinuria at 
onset. Of patients with nephrotic or nephritic-nephrotic features, 68% had a good outcome 
and specifically 59% of them achieved complete recovery. Level of urinary 
albumins/creatinine ratio at 1 year above or below 144 mg/mmol discriminated between 
poor and good outcome with a sensitivity of 95% and specificity of 40%, positive predictive 
value 82%, negative predictive value 73% (Edström Halling et al., 2010). 
Patients with a poor outcome had lower Glomerular Filtration Rate than patients with a 
good outcome. An initial renal insufficiency was a predictor of poor renal outcome in 
Henoch-Schönlein purpura nephritis (Edström Halling et al., 2010). 
There was no difference in outcome between patients who were normotensive and those 
who were hypertensive at the first investigation (Edström Halling et al., 2010).  
9.2 Prognostic factors and biopsy findings 
International Study of Kidney Disease in Children grading score and proteinuria at the 1-
year follow-up were the best discriminators of a good and poor outcome (Edström Halling 
et al., 2010). 
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Kawasaki (Kawasaki et al., 2003) classified Henoch-Schönlein purpura nephritis patients 
with International Study of Kidney Disease in Children grade IIIb or higher as having 
severe disease. Shenoy (Shenoy et al., 2007) concluded that most children with Henoch-
Schönlein purpura nephritis grade IIIb or higher on initial biopsy had persistent renal 
abnormalities at long-term follow-up. The risks for long-term renal impairment are highest 
in children who present and/or with more than 50% of glomeruli (grade IV or above) 
occupied by large crescents or sclerosing lesions (Bogdanovic, 2009) because they showed 
higher probabilities for development of progressive renal disease, renal failure, or end-stage 
renal disease after long-term follow-up (Iijima et al., 1998; Kawasaki et al., 2004; Niaudet & 
Habib, 1998).  
Patients with segmental glomerulosclerosis had a poorer outcome than those without 
segmental glomerulosclerosis. The comparison of patients with crescents to those without or 
those with global glomerulosclerosis to those without revealed no difference in outcome. 
Patients with poor outcome had a higher degree of mesangial matrix expansion, mesangial 
proliferation, interstitial inflammation and interstitial fibrosis than did those with a good 
outcome. Crescents were not a factor of poor prognosis, but the majority of the patients with 
crescents were treated, which may have improved the course of the disease (Edström 
Halling et al., 2010). 
10. Conclusion 
At this time, randomized controlled trials are needed to demonstrate whether the present 
management with conventional and adjuvant treatments improve truly renal survival of 
patients with Henoch-Schönlein purpura nephritis. Anymore, the choice of the treatment 
must depend on both the histological and clinical severity of the Henoch-Schönlein purpura 
nephritis. In particular, recommendations include a combination therapy for clinically and 
histologically severe Henoch-Schönlein purpura nephritis, which is unnecessary for 
moderate Henoch-Schönlein purpura nephritis.  
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